Option chain shows key data for Revive Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Revive Therapeutics.

Revive Therapeutics (OTC:RVVTF) Stock, Option Chain

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

image006

Cannabis

Psychedelics

Exclusives

ATAI

CMPS

CSE:HAVN

CSE:TRIP

CYBN

HAVLF

MNMD

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

RVVTF

SEEL

TRIP

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves

News

Penny Stocks

Events

Markets

IGXT

NUMIF

PHRRF

SILO

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition &amp; Failing Mechanism

A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin is a constitutional right under the Canadian Charter of Rights and Freedoms.

Psyched: Canada&#39;s Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA &amp; More

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update

REVIVE THERAPEUTICS LTD by Revive Therapeutics Ltd.

Revive Therapeutics Ltd

Health Care

Press Releases

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Contracts

Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program

DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis

Comments

Revive Therapeutics

Revive Therapeutics (RVVTF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga